# Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

> **NCT01172054** · PHASE1 · COMPLETED · sponsor: **VaxInnate Corporation** · enrollment: 292 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** VAX128
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01172054
- **Lead sponsor:** VaxInnate Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-12
- **Final completion:** 2011-11
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2012-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01172054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01172054, "Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01172054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*